Medicenna Therapeutics logo

Medicenna Therapeutics(TSX) MDNA

Market CapCA$34.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-84%
5 Year-85%
1 Year-52%
1 Month+5%
CA$0.44
+0.00%
+0.00Today
Medicenna Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 0.442026-10-14
Medicenna Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.22%CAD 0.452026-10-07
1 month+4.76%CAD 0.422026-09-14
3 month+25.71%CAD 0.352026-07-16
Year to date-52.17%CAD 0.922025-12-31
1 year-52.17%CAD 0.922025-10-14
3 year+11.39%CAD 0.402023-10-13
5 year-85.28%CAD 2.992021-10-15
Since inception-83.7%CAD 2.702017-03-08

Medicenna Therapeutics Financials at a Glance

Market Cap

CA$34.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$18.56M

EPS (TTM)

-CA$0.22

P/E Ratio

-2.00

Dividend

CA$0.00

Beta (Volatility)

1.04 (Average)

Price

CA$0.44

Volume

10,650

Open

CA$0.45

Previous Close

CA$0.44

Daily Range

CA$0.44 - CA$0.45

52-Week Range

CA$0.34 - CA$1.97

Estimated Earnings Date

Nov 12, 2026

MDNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is an innovative immunotherapy company dedicated to developing and commercializing Superkines and "empowered Superkines" for cancer treatment and other diseases. The company’s lead candidate, MDNA55, has completed Phase IIb trials for recurrent glioblastoma and is being explored for various tumor types.

Products and Services
  • MDNA55: An interleukin-4 empowered cytokine for glioblastoma
  • MDNA11: An improved IL-2 variant targeting cancer
  • BiSKITs platform: Custom-engineered Superkines for therapeutic applications
Growth Outlook
  • MDNA55 shows promise in ongoing clinical trials, potentially expanding market opportunities
  • Pipeline includes multiple candidates addressing various cancers and autoimmune diseases
  • Strategic partnerships may enhance research capabilities and accelerate development timelines
Financial Highlights
  • Recent quarterly net income of -$5.08 million reflects ongoing investment in R&D
  • Cash and cash equivalents of $5.69 million provide operational runway for upcoming projects
  • Trailing twelve months (TTM) cash flow indicates a focus on long-term growth despite current losses
Medicenna Therapeutics Corp. operates in the biotechnology sector, focusing on groundbreaking therapies that leverage the body's immune system to fight cancer. The company’s innovative approach, particularly with its Superkines technology, positions it uniquely within the competitive landscape of cancer treatment. The ongoing clinical trials and a robust pipeline suggest potential for significant advancements in therapeutic options for patients. Financially, while the company is currently operating at a loss, the available cash reserves and strategic focus on research and development indicate a commitment to long-term growth and innovation in the healthcare sector.
AI Generated • Oct 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

20

CEO

Fahar Merchant, PhD

Website

www.medicenna.com

Headquarters

Toronto, ON M4W 3E2, CA

MDNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-360.29%

Return on Capital

-911.57%

Return on Assets

-225.03%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$34.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

77.62M

Volume

10.65K

Avg. Volume

45.29K

Financials (TTM)

Gross Profit

-CA$75.00K

Operating Income

-CA$23.65M

EBITDA

-CA$22.99M

Operating Cash Flow

-CA$18.81M

Capital Expenditure

CA$9.44M

Free Cash Flow

-CA$14.33M

Cash & ST Invst.

CA$5.69M

Total Debt

CA$104.00K

Medicenna Therapeutics Performance Analysis

Medicenna Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 0N/A
20242024-03-31CAD 0N/A
20252025-03-31CAD 0N/A
20262026-03-31CAD 0N/A
Medicenna Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Q12026-06-30N/A
Medicenna Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.16-62.7%
20242024-03-31CAD -0.37135.6%
20252025-03-31CAD -0.15-57.9%
20262026-03-31CAD -0.2243.7%
Medicenna Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-302.0%
Q32025-12-3110.6%
Q42026-03-312.9%
Q12026-06-30-15.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$17.00K

+10.5%

Gross Margin

0.00%

N/A

Market Cap

CA$34.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.28M

N/A

Employees

15

N/A

Net Income

-CA$5.08M

-3.1%

EBITDA

-CA$5.43M

+1.0%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

CA$5.69M

-72.2%

Total Debt

CA$104.00K

-35.8%

Accounts Receivable

CA$1.52M

+29.9%

Inventory

CA$0.00

N/A

Long Term Debt

CA$33.00K

-68.3%

Short Term Debt

CA$71.00K

+22.4%

Return on Assets

-2.25%

N/A

Return on Invested Capital

-13.45%

N/A

Free Cash Flow

-CA$4.43M

-24.9%

Operating Cash Flow

-CA$4.43M

-24.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SVA.TOSernova Corp.
CA$0.12+0.00%
MIR.VMedMira Inc.
CA$0.07+0.00%
ZEN.VZentek Ltd.
CA$0.61-1.61%
COV.VCovalon Technologies Ltd.
CA$4.04+2.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.63-0.13%
INTCIntel
$95.37-2.80%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
CRWVCoreWeave
$69.69+5.94%

Questions About MDNA

What is the current price of Medicenna Therapeutics?

Medicenna Therapeutics is trading at CA$0.44 per share.

What is the 52-week range for Medicenna Therapeutics?

Over the past 52 weeks, Medicenna Therapeutics has traded between CA$0.34 and CA$1.97.

How much debt does Medicenna Therapeutics have?

As of the most recent reporting period, Medicenna Therapeutics reported total debt of CA$104.00K.

How much cash does Medicenna Therapeutics have on hand?

Medicenna Therapeutics reported CA$5.69M in cash and cash equivalents in its most recent financial results.

What is Medicenna Therapeutics’s dividend yield?

Medicenna Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services